# Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B

> **NCT00071201** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 48 (—)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Adefovir Dipivoxil for oral suspension, 2 mg/mL

## Key facts

- **NCT ID:** NCT00071201
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 48 (—)
- **Last updated:** 2013-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00071201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00071201, "Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00071201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*